Incidence and risk factors for hyperkalaemia in patients treated for COVID‐19 with nafamostat mesylate
Author:
Affiliation:
1. Department of Pharmacy Nihon University Itabashi Hospital Itabashi‐ku Japan
2. Division of Respiratory Medicine Department of Internal Medicine Nihon University School of Medicine Itabashi‐ku Japan
Publisher
Hindawi Limited
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13646
Reference43 articles.
1. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
2. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
3. World Health Organization.Coronavirus disease (COVID‐19) n.d.https://covid19.who.intAccessed December 27 2021
4. World Health Organization.Novel Coronavirus (2019‐nCoV) Situation Report ‐ 22 2020.https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/20200211‐sitrep‐22‐ncov.pdfAccessed September 15 2021
5. Recent progress of antiviral therapy for coronavirus disease 2019
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis;Japanese Journal of Infectious Diseases;2024-05-31
2. A Randomized Trial of Nafamostat for Covid-19;NEJM Evidence;2023-10-24
3. New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System;Journal of the Renin-Angiotensin-Aldosterone System;2023-07-12
4. Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins;Biomolecules;2023-03-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3